-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to support company's 5x30 path to becoming an innovative biopharmaceutical organization -- PARSIPPANY, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced two key appointments to its executive leadership team. Brendan Tee ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

Core Viewpoint - A securities class action has been filed on behalf of shareholders of Pacira BioSciences, Inc. (PCRX), indicating potential legal challenges for the company related to its securities practices [1] Group 1: Legal Action - The lawsuit aims to address alleged violations of securities laws by Pacira BioSciences, which may impact the company's reputation and financial standing [1] - The filing of the class action suggests that shareholders believe they have been harmed by the company's actions, which could lead to financial liabilities for Pacira [1] Group 2: Shareholder Impact - Shareholders are seeking to recover losses incurred due to the alleged misconduct, highlighting the importance of corporate governance and transparency in the biotech industry [1] - The outcome of this legal action could set a precedent for how similar cases are handled in the future, potentially affecting investor confidence in the sector [1]

Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors - Contact Levi & Korsinsky ...

Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...

PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

Lawsuit Overview - Pacira BioSciences and certain executives are charged with failing to disclose material information during the Class Period, violating federal securities laws [3] - The lawsuit is pending in the United States District Court for the District of New Jersey [1] Key Events - On August 9, 2024, Pacira released results of its lawsuit against eVenus for patent infringement related to Exparel, which accounts for approximately 80% of the company's revenue [4] - The U S District Court for the District of New Jersey found that Pacira's U S Patent No 11,033,495 is not valid, meaning eVenus was not infringing on anything [4] - Following this news, Pacira's share price fell over 47%, from $22 36 per share on August 8, 2024 to a low of $11 70 per share on August 9, 2024 [5] Legal Actions - Investors who purchased Pacira securities between August 2, 2023 and August 8, 2024 have until March 14, 2025 to file lead plaintiff applications in the securities class action lawsuit [1] - The case is titled Alvarez v Pacira BioSciences, Inc, et al, No 25-cv-00322 [5]

Pacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – PCRX ...

Core Viewpoint - A class action lawsuit has been filed against Pacira BioSciences, Inc. for allegedly failing to disclose insufficient patent protection for its key product, Exparel, which significantly impacted its stock value [1][2][3]. Group 1: Allegations and Impact - The lawsuit claims that Pacira misled investors about the strength of its patent protections for Exparel, which is crucial for the company's growth and revenue [2][3]. - The '495 patent, which was believed to protect Exparel, was invalidated in a court ruling, leading to concerns that generic versions could enter the market, jeopardizing approximately 80% of Pacira's revenue [3]. - Following the announcement of the patent loss on August 9, 2024, Pacira's stock price plummeted from $22.36 to $11.70, a decline of over 47% in one day [3]. Group 2: Class Action Participation - Investors who purchased Pacira securities between August 2, 2023, and August 8, 2024, may be eligible to participate in the class action [1][4]. - Shareholders interested in serving as lead plaintiffs must submit their applications by March 14, 2025, but participation is not required to be eligible for recovery [4]. Group 3: Company Background - Pacira BioSciences, Inc. is an American pharmaceutical company focused on developing non-opioid pain management and regenerative health solutions [1].

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX ...